Parecer de pré-exame
#6.23
04/01/2025
RPI 2830
Application data
Number
112020012637Type
Filing
Publication
PCT
US2018066583 The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.
Latest action published by the INPI: 04/01/2025. We update with every new RPI gazette, published weekly.
Applicants
SHIRE HUMAN GENETIC THERAPIES, INC
US
TAKEDA PHARMACEUTICAL COMPANY LIMITED
JP
Inventors
A. K. (pessoa física)
US
G. E. (pessoa física)
US
IPC Classification
Priority claims
US
62/607,831 · 12/19/2017
US
62/608,569 · 12/20/2017
US
62/625,814 · 02/02/2018
US
62/760,597 · 11/13/2018
Abstract
A presente invenção fornece, entre outras coisas, métodos de tratamento da Doença de Leucodistrofia Metacromática (MLD) e composições compreendendo a proteína arilsulfatase A recombinante (ASA) usando terapia de reposição enzimática.
Publications in the Brazilian Industrial Property Gazette (RPI).
#6.23
04/01/2025
RPI 2830
#25.1
12/28/2021
RPI 2660
#15.35
12/07/2021
RPI 2657
#1.3
12/01/2020
RPI 2604
#1.1
10/20/2020
RPI 2598
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.